MacroChem Retains The Investor Relations Group

Wellesley Hills, Massachusetts (ots/PRNewswire) -

MacroChem Corporation (OTC Bulletin Board: MACM), a specialty
pharmaceutical company that develops and seeks to commercialize
pharmaceutical products based on proprietary drug delivery
technologies, has retained The Investor Relations Group, Inc. (IRG),
a full-service investor relations firm, to serve as its new investor
relations and corporate communications agency.

"The Investor Relations Group will play an integral role in
ensuring that MacroChem reaches the investment community by
incorporating a more proactive program," said Robert DeLuccia,
President and CEO of MacroChem Corporation. "We believe IRG will also
help us deliver our Company messages more effectively to investors
and financial sources."

IRG will strive to increase investor and industry awareness of
MacroChem and its products within the U.S. and world markets by
introducing the Company and its Management to pre-qualified fund
managers and analysts, as well as to financial and industry media
sources.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company with
two clinical development stage products containing our patented
enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and
Opterone(R), to treat male hypogonadism. In addition to our SEPA
technology, we are also evaluating applications for MacroDerm(TM),
our patented series of polymers that impede penetration of active
ingredients through the skin. For more information visit our website,
http://www.macrochem.com.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG), founded in 1996,
represents select publicly traded companies, with a unique
specialization in assisting quality under-followed companies. IRG
arranges one-on-one meetings for its portfolio companies with
pre-qualified money managers, handling investment portfolios that
range from US$10 million to US$10 billion+, selected from its
proprietary contact base of more than 50,000 qualified fund managers
with an investing history in small-cap stocks. IRG is a full-service
corporate communications company that, among other related offerings,
produces all client press releases, manages shareholder
communications and acts as primary contact for the investing
community. IRG also houses a full-service public relations arm that
specializes in building awareness of its companies within the
financial and trade media, as well as the public at large.

Forward-Looking Statements

With the exception of historical information contained in this
press release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection and dependence on third parties for
development and licensing arrangements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. MacroChem undertakes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise. For more information
visit our website, http://www.macrochem.com.

Contact:
MacroChem Corp.: Bernard Patriacca - VP/CFO
+1-781-489-7310
Investor Relations: The Investor Relations Group, Inc.
Jordan Silverstein/Christine Berni
+1-212-825-3210

Web site: http://www.macrochem.com

ots Originaltext: MacroChem Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bernard Patriacca, VP/CFO of MacroChem Corp., +1-781-489-7310; or
Jordan Silverstein or Christine Berni of The Investor Relations
Group, Inc., +1-212- 825-3210